Pharmacy Accreditation
|
|
- Cassandra Pope
- 5 years ago
- Views:
Transcription
1 The Evolving Role of Specialty Pharmacists in Cancer Immunotherapy: New Pathways, Agents, Opportunities, and Challenges Patrick J. Medina, PharmD, BCOP Professor Department of Medicine Stephenson Cancer Center University of Oklahoma Oklahoma City, Oklahoma Pharmacy Accreditation Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number L01-P. The activity is available for CE credit through May 4, Faculty Disclosure Patrick Medina, PharmD, BCOP, has no relevant financial relationships with commercial interest to disclose.
2 This activity is sponsored by Pharmacy Times Continuing Education and supported by an educational grant from Bristol-Myers Squibb. Learning Objectives Explain the mechanisms of action behind immune response to cancer and the role of immunotherapy in cancer treatment Distinguish new and emerging immunotherapy classes and individual agents and their efficacy, safety, and potential patient responses to therapy in cancer treatment Examine strategies to counsel and assist patients to overcome barriers to therapy, including treatment side effects to improve adherence to therapy Immunotherapy History Paul Erlich in the late 1800s described the term Magic Bullet The basic theory is related to the thought that tumor cells express an antigenic profile distinct from normal cells Immune system is capable of recognizing these antigenic differences In addition, tumor cells turn off T-cells specific for tumor antigens Pardoll D. Semin Oncol. 2015;42(4):523-38
3 How Do Tumor Cells Differ From Normal Cells? Clonal in origin Dysregulated growth and lifespan Altered tissue affinity Resistance to apoptosis Change in surface phenotypes and markers Structure and biochemical changes Altered gene expression Presence of tumor specific antigens Hanahan D, et al. Cell. 2011;144(5): Emerging Hallmarks of Cancer Reprinted from Cell, 144(5), Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation , Copyright (2011), with permission from Elsevier. Immune Surveillance Reprinted from Semin Oncol, 42(4), Pardoll D, Cancer and the Immune System: Basic Concepts and Targets for Intervention, , Copyright (2015), with permission from Elsevier.
4 Immune Checkpoints Cell surface receptors Bind to ligand to modulate immune responses CTLA-4 and PD-1 are the best characterized, but many others exist CTLA-4 is thought to limit T-cell activity early in the immune response PD-1 is thought to reduce T-cell activity later, during the course of the immune response PD-1 may also be important for the suppressive function of regulatory T-cells Medina PJ, et al. Pharmacotherapy. 2016;36(3): ; Ferreri AJ, et al. Nat Rev Clin Oncol. 2010;7(8):doi: /nrclinonc c1 Targeting the Hallmarks of Cancer Reprinted from Cell, 144(5), Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation , Copyright (2011), with permission from Elsevier. Types of Immunotherapy Monoclonal antibodies Bevacizumab, rituximab, and many others Direct tumor effects Complement-dependent cytotoxicity (CDCC) Antibody-dependent cellular cytotoxicity (ADCC) Cancer vaccines BCG, Sipuleucel-T, HPV Non-specific immune boosters Interleukin-2, interferon Adoptive T-cell therapy (Chimeric antigen receptor [CAR] T-cell therapy) Immune checkpoint inhibitors CTLA-4 and PD-1 monoclonal antibodies Scott AM, et al. Nat Rev Cancer. 2012;12(4):
5 Immunotherapy Vaccinations BCG live vaccine Stimulates the host to reject the tumor Injected into the bladder for bladder cancer Causes local response to tumor Non-specific HPV-16 vaccine HPV commonly linked to cervical cancer Gandhi NM, et al. BJU Int. 2013;112(3): ; Beavis AL, et al. Front Oncol. 2016;6:19. HPV Vaccine Specific immunotherapy Merck (first of 2) Approved in 2006 (Gardasil) Subtypes 16, 18, 6, 11 ~70% of high-risk types for cervical cancer ~90% of types for anogenital warts Also associated with head and neck cancers Lifetime effectiveness? 3 years Who? 9-26 year olds Others at risk Beavis AL, et al. Front Oncol. 2016;6:19. Sipuleucel T (Provenge) Adoptive cellular immunotherapy Patients undergo 3 rounds of leukapheresis Cells then sent to Dendreon: Antigen-presenting cells (APCs) are isolated and cultured with PA2024 PA2024 is a recombinant fusion protein, which serves as immunogen: Prostatic acid phosphatase and GM-CSF 3 doses of treated cells are administered to patients, each 2 weeks apart Sonpavde G, et al. Eur Urol. 2012;61(4):
6 Sipuleucel-T: Patient-Specific Therapy Reprinted from Eur Urol, 61(4), Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND, The role of sipuleucel-t in therapy for castration-resistant prostate cancer: a critical analysis of the literature, , Copyright (2012), with permission from Elsevier. Talimogene laherparepvec (Imlygic) Based on the herpes simplex virus, type I (HSV-1) Modified by deleting the neurovirulence genes preventing fever blister development and deleting a viral gene that blocks antigen presentation T-VEC can target and replicate in cancer cells by using surface-bound nectins to enter the cell and preferentially replicates in tumor cells by exploiting disrupted oncogenic and antiviral signaling pathways, Also generates an immune response, which is likely enhanced by the expression of GM-CSF Lawler SE, et al. J Clin Oncol. 2015;33(25): Talimogene laherparepvec FDA approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery Recommended starting dose is up to a maximum of 4 ml at a concentration of 10 6 plaque-forming units (PFU) per ml Subsequent doses should be administered up to 4 ml at a concentration of 10 8 PFU per ml Shipped frozen, needs to be thawed up to 48 hours Warnings for accidental exposure leading to herpetic infections in health care workers, herpetic infections, injection site complications, immune-mediated events, and plasmacytoma at injection site Herpetic infections sensitive to acyclovir and may decrease the efficacy, use caution This is a live virus; exposure precautions are necessary Imlygic (Talimogene laherparepvec) [package insert]. Thousand Oaks, CA: Amgen; 2015.
7 Antitumor Activity of Talimogene Iaherparepvec More than half experienced 25% increase in the size of lesions or appearance of new lesions before achieving a response Two-thirds of responses expected to be > 1 year Andtbacka RH, et al. J Clin Oncol. 2015;33(25): Cytokines Produced by mononuclear cells Activate the immune system to attack the cancer NK cells, lymphocytes, etc. Proteins produced with recombinant technology Short t1/2 Pharmacy principles Do not shake, refrigerate Dranoff G. Nat Rev Cancer. 2004;4(1): Interferon-alfa (Intron-A) Naturally-occurring protein Secreted by cells in response to viral infections, tumors, and other biological inducers Produce clinical benefits for disease states, such as cancer, hepatitis, and multiple sclerosis Produce general antiprolifertive effects on cancer cells and/or activate the immune system to fight the cancer Used in melanoma, myeloma, and renal cell Accessed April 1, 2016.
8 Interleukin-2 (Aldesleukin, Proleukin) Endogenous source: T lymphocytes Activity Growth factor for T-cells Stimulation of cytotoxicity in NK and T-cells Cofactor in activating macrophages and B cells Main therapeutic uses Renal cell carcinoma Malignant melanoma Accessed April 1, Interleukin-2 Adverse reactions Black box warning Vascular leak syndrome Increased risk of infection Cardiac arrhythmias End organ damage Infusion related reactions Proleukin (Interleukin-2) [package insert]. San Diego, CA: Prometheus Laboratories Inc.; Denileukin Diftitox (Ontak) Interleukin-2 fused with diphtheria toxin Activity 1. Binds to IL-2 receptor 2. Is internalized, releasing diphtheria toxin into cytosol 3. Inhibits protein synthesis, resulting in cellular death Baldo BA. Drug Saf. 2015;38(5):
9 Denileukin Diftitox Main therapeutic uses Acute graft-versus-host disease Cutaneous T-cell lymphoma Chronic lymphocytic leukemia Adverse reactions Acute hypersensitivity Same as with IL-2 alone Baldo BA. Drug Saf. 2015;38(5): Ipilimumab (Yervoy) Mechanism of action Human monoclonal antibody against CTLA-4 FDA approved for treatment of melanoma Lipson EJ. Clin Cancer Res. 2011;17(22): Ipilimumab Unresectable or metastatic melanoma 3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of 4 doses Unresectable or metastatic melanoma, in combination with nivolumab at the same dose Adjuvant melanoma 10 mg/kg administered intravenously over 90 minutes every 3 weeks for 4 doses, followed by 10 mg/kg every 12 weeks for up to 3 years or until documented disease recurrence or unacceptable toxicity Yervoy (Ipilimumab ) [package insert]. Princeton, NJ: Bristol Myers Squibb; 2015.; Opdivo (Nivolumab) [package insert]. Princeton, NJ: Bristol Myers Squibb 2015.
10 Ipilimumab: Safety The most common adverse reactions ( 5%) in patients who received 10 mg/kg were: Rash (50%) Diarrhea (49%) Fatigue (46%) Pruritus (45%) Headache (33%) Weight loss (32%) Nausea (25%) Pyrexia (18%) Colitis (16%) Decreased appetite (14%) Vomiting (13%) Insomnia (10%) Yervoy (Ipilimumab ) [package insert]. Princeton, NJ: Bristol Myers Squibb; 2015 The most common adverse reactions ( 5%) in patients who received 3 mg/kg were: Fatigue (41%) Diarrhea (32% Pruritus (31% Rash (29%) Colitis (8%) Immune-mediated adverse reactions (n = 131) Grade (3-5) (%) Any Immune Reaction 15 Enterocolitis 7 Hypo/hyperthyroidism 4 Dermatitis 2 Hepatotoxicity 1 Neurotoxicity 1 Nephritis 1 Kinetics of Appearance of Ipilimumab Immune-related Adverse Events Printed with permission from Weber JS. J Clin Oncol. 2012;30(21): Overall Survival and Progression-free Survival for Ipilimumab in Metastatic Melanoma Time to response 3.18 months Printed with permission from Hodi FS. N Engl J Med ;363(8):
11 Nivolumab (Opdivo) A human IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 FDA approved for: Unresectable or metastatic melanoma, as a single agent Unresectable or metastatic melanoma, in combination with ipilimumab Metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving nivolumab Advanced renal cell carcinoma who have received prior antiangiogenic therapy The dose is 3 mg/kg every 2 weeks with the exception of when it is used in combination with ipilimumab (dose is 1 mg/kg, followed by ipilimumab on the same day, every 3 weeks for 4 doses, then 3 mg/kg every 2 weeks) Opdivo (Nivolumab) [package insert]. Princeton, NJ: Bristol Myers Squibb Nivolumab: Safety Most common adverse reactions ( 20%) in patients with metastatic NSCLC were fatigue, musculoskeletal pain, decreased appetite, cough, and constipation. Immune adverse reactions (n = 287) Any Grade (%) Median Time to Onset (Months) Pneumonitis Enterocolitis Adrenal Insufficiency 0.3 NR Renal Toxicity Hepatotoxicity Hypothyroid Hyperthyroid Rash 6 NR Opdivo (Nivolumab) [package insert]. Princeton, NJ: Bristol Myers Squibb Nivolumab in NSCLC From N Engl J Med, Borghaei H, et al, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, 373: Copyright (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
12 Nivolumab in NSCLC From N Engl J Med, Borghaei H, et al, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, 373: Copyright (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Pembrolizumab (Keytruda) A humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD- L2 FDA approved for: Unresectable or metastatic melanoma, as a single agent Metastatic NSCLC whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab The dose is 2 mg/kg every 3 weeks Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc. Pembrolizumab: Safety The most common adverse reactions ( 20%): Fatigue (47%) Cough (30%) Nausea (30%) Pruritus (30%) Rash (29%) Decreased appetite (26%) Constipation (21%) Arthralgia (20%) Diarrhea (20%) Immune-mediated adverse reactions (n = 411) Median onset All grades n (%) Hepatitis 22 days 2 (0.5) Hypo/hyperthyroidism 1.5 mo. 5 (1.2) Hypophysitis 1.7 mo. 2 (0.5) Pneumonitis 5 mo. 12 (2.9) Colitis 6.5 mo. 4 (1) Nephritis 11.6 mo. 3 (0.7) Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.
13 Pembrolizumab vs Ipilimumab in Metastatic Melanoma From N Engl J Med, Robert et al, Pembrolizumab versus Ipilimumab in Advanced Melanoma, 372: Copyright (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Pembrolizumab vs Ipilimumab in Metastatic Melanoma From N Engl J Med, Robert et al, Pembrolizumab versus Ipilimumab in Advanced Melanoma, 372: Copyright (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Adverse Events in the As-Treated Population From N Engl J Med, Robert et al, Pembrolizumab versus Ipilimumab in Advanced Melanoma, 372: Copyright (2015) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
14 Immunotherapy Introduces a New Era of Toxicity Management Immune-related adverse events (iraes) The 5 Pillars of Immunotherapy Toxicity Management Printed with permission from Champiat S. Ann Oncol. 2016;27(4): Enterocolitis/ Pneumonitis/ Neuropathies* Grade 1 (< 4 stools/day over baseline) Monitor and continue therapy Grade 2 (4-6 stools/day over baseline) Monitor and continue therapy when grade 1 Symptoms persist, start prednisone 1mg/kg/day with a 4 week taper and continue therapy when grade 1 If symptoms persist or relapse on taper start IV steroids Grade 3/4 IV methylprednisolone 2 mg/kg and discontinue therapy (GI consult and hospitalization recommended) Consider infliximab 5 mg/kg IV ever 2 weeks if symptoms persist *Please consult current package insert for individual products Fecher LA, et al. Oncologist 2013;18(6): ; Champiate S, et al. Ann Oncol. 2016;27(4):
15 Baseline: Emollients ± skin moisturizers Hepatitis* Grade 1 - AST or ALT <1-2.5 X the upper limit of normal (ULN), or total bilirubin X the ULN Monitor and continue therapy Grade 2 - AST or ALT >2.5-5 X the ULN, or total bilirubin >1.5-3 X the ULN Monitor and continue therapy when grade 1 Symptoms persist, start prednisone 1mg/kg/day with a 4 week taper and continue therapy when grade 1 If symptoms persist or relapse on taper start IV steroids Grade 3/4 - AST or ALT >5 X the ULN, or total bilirubin >3 times the ULN IV methylprednisolone 2 mg/kg and discontinue (consider hepatology consult and hospitalization recommended) Consider if symptoms persist mycophenolate 500 mg PO every 12 hours *Please consult current package insert for individual products Fecher LA, et al. Oncologist 2013;18(6): ; Champiat S, et al. Ann Oncol. 2016;27(4): Dermatitis* Signs/symptoms: Rash < 30% of the body surface Dry skin Pruritus (localized) Vitiligo *Please consult current package insert for individual products Signs/symptoms: Rash > 30% of the body surface Pruritus (diffuse and constant) Blisters, ulcerations, bullae, necrotic or hemorrhagic lesions Toxic epidermal necrolysis Printed with permission from Fecher. The Oncologist. 2013;18: Grade 1 Moisturizers Topical steroids Monitor Continue therapy Grade 2 Topical steroids Antihistamines Persistent symptoms > 1-2 weeks start oral prednisone 1 mg/kg/day Dermatology consult Restart when grade 1 or less Grade 3 or 4 Systemic steroids (taper over 4 weeks after symptoms resolve) May need hospitalization Dermatology consult Discontinue therapy (may consider restarting if grade 3 and resolution of symptoms) Tumor Immunotherapy: Tips Counseling Diarrhea Shortness of breath, chest pain, cough Weight gain/loss, muscle aches, abdominal pain Headaches, weakness, vision changes Decreased urine output Monitoring Liver function tests, serum creatinine, thyroid function Signs/symptoms of immune-mediated adverse reaction (pneumonitis, colitis, etc.) Treatment Corticosteroid until improvement to grade 1 or less and then taper over 1 month
16 Patient ID Card Name, Family name: Immunotherapy drug(s): I am currently receiving an immunotherapy, which may increase the risk of occurrence of autoimmune diseases and in particular: pneumonitis (inflammation of the lungs) colitis (inflammation of the gut) hepatitis (inflammation of the liver) nephritis (inflammation of the kidneys) endocrinopathy: hypophysitis, thyroid dysfunction, diabetes, adrenal insufficiency (inflammation of the hormone producing organs) cutaneous rash (inflammation of the skin) as well as other immune-related adverse events: neurological, hematological, ophthalmological, The management of these dysimmune adverse events is specific and sometimes urgent. It absolutely requires coordination with the health care team which has prescribed the treatment: Prescriber ID and contact information (reported at the back of this card) Champiat S, et al. Ann Oncol. 2016;27(4): Barriers to Care Cost Melanoma Ipilimumab $158,282 Nivolumab $103,220 Pembrolizumab $14,500/month at lower dose (up to 1 million per year if higher doses used) Talimogene $65,000/dose Combination of ipilimumab + nivolumab $295,566 Patient with a 20% co-pay = $60,000 out of their own pocket All companies have patient support programs that should be routinely used Adverse effect management can be tricky, and patients may have to come off and on drugs Responses often take time, pseudoprogression is possible Andrews A. Am Health Drug Benefits. 2015; 8(Spec Issue): 9. Additional Resources American Cancer Society eeffects/treatmenttypes/immunotherapy/index Research Cancer Immunotherapy National Cancer Institute mmunotherapy-using-immune-system
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationYervoy. Yervoy (ipilimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 4 Last Review Date: March 18, 2016 Yervoy Description Yervoy (ipilimumab)
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationPEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate Day 1 Pembrolizumab 2mg/kg IV Infusion 100mL 0.9% Sodium Chloride* Or 100mL 5% Glucose* *Final concentration must be between 1 to 10mg/mL Over
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationATEZOLIZUMAB (TECENTRIQ )
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationImmune-Related Adverse Reaction (irar) Management Guide
REGIMEN Immune-Related Adverse Reaction (irar) Management Guide OPDIVO as monotherapy is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) with progression
More informationNECN CHEMOTHERAPY HANDBOOK PROTOCOL
Nivolumab (Opdivo ) for treatment of advanced melanoma and Renal Cell Cancer (Also advanced/ metastatic NSCLC EMAS patients only -Nov 2016) DRUG ADMINISTRATION SCHEDULE (SINGLE AGENT Day Drug Daily dose
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationImmunotherapy: Toxicity Management. Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital
Immunotherapy: Toxicity Management Dr. Megan Lyle Medical Oncologist Liz Plummer Cancer Care Centre Cairns Hospital Disclosures Honoraria and travel support from BMS, MSD, Novartis Advisory board for MSD
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationNivolumab and Ipilimumab
Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationBristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the
More informationENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY
ENDOCRINE ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT IMMUNOTHERAPY Lauren Clarine DO, Renil Rodriguez Martinez MD, Matthew Levine MD, Amy Chang MD, and Megan McGarvey MD May 6, 2017 Immune checkpoint inhibitors
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationIpilimumab in Melanoma
Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationNursing Perspective on iraes: Patient Education, Monitoring and Management
Nursing Perspective on iraes: Patient Education, Monitoring and Management Rebecca Lewis, CRNP Nurse Practitioner University of Pittsburgh-HCC Shadyside Disclosures No relevant financial relationships
More informationCancer Immunotherapy Future from the Past?
Disclaimer This talk is intended for educational value, and includes comments on unlicensed drugs. Please liaise with a specialist if you have a clinical query. Cancer Immunotherapy Future from the Past?
More informationManagement of Immune Checkpoint Inhibitor Related Toxicities
Management of Immune Checkpoint Inhibitor Related Toxicities Katie Wolfram, PharmD Clinical Pharmacist, Oncology Memorial Hospital of South Bend A Webinar for HealthTrust Members November 12, 2018 Disclosures
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationHealthcare Professional. Frequently Asked. Questions. Brochure
YERVOY (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure YERVOY is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. 1 This medicinal product
More informationOPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS
OPTIMAL MANAGEMENT OF IMMUNE- RELATED ADVERSE EVENTS ASSOCIATED WITH CHECKPOINT INHIBITORS Alberto Fusi Charité Comprehensive Cancer Centre Berlin, Germany 1 Immune check point blockade with CTLA-4, anti-pd-1
More informationNon-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,
More information9/21/2016. Disclosures. Objectives. Patient Case: RF. Cytotoxic Chemotherapy Timeline. Evolution of Cancer Treatment: The Immune System Versus Cancer
1 2 Disclosures Nothing to disclose at this time. Evolution of Cancer Treatment: The Immune System Versus Cancer Megan Hames Pollack, PharmD, BCOP, BCPS Clinical Pharmacist, Outpatient Medical Oncology
More informationMelanoma Immunotherapy. Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management
Melanoma Immunotherapy Nursing Perspective on Immune-Related Adverse Events: Patient education, Monitoring & Management Mike Buljan, NP UCSF Medical Center Melanoma Oncology Disclosures None Only FDA-approved
More informationBristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
January 20, 2017 Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer (PRINCETON, NJ, January 19, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) announced that it has decided not
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationFirst and only FDA-approved combination of two Immuno-Oncology agents 1
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma First
More informationEuropean Medicines Agency Validates Bristol-Myers Squibb s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer
September 21, 2016 European Medicines Agency Validates Bristol-Myers Squibb s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer (PRINCETON, NJ, September 20, 2016)
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Ipilimumab (Yervoy) Reference Number: CP.PHAR.319 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationFDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer
March 5, 2015 FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer (PRINCETON, NJ, March 4, 2015) Bristol-Myers Squibb Company
More informationBC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab
BC Cancer Protocol Summary for Treatment of Advanced Non- Small Cell Lung Cancer Using Pembrolizumab Protocol Code Tumour Group Contact Physician ULUAVPMB Lung Dr. Christopher Lee ELIGIBILITY: Advanced
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationUnderstanding your treatment and the side effects you may experience
Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationAttached from the following page is the press release made by BMS for your information.
September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September
More informationPembrolizumab 200mg Monotherapy
Pembrolizumab 200mg This regimen supercedes NCCP Regimen 00347 Pembrolizumab 2mg/kg as of September 2018 due to a change in the licensed dosing posology. INDICATIONS FOR USE: INDICATION ICD10 Regimen Code
More informationImmunotherapies in Solid Tumors
Immunotherapies in Solid Tumors Val R. Adams, PharmD, FCCP, BCOP Associate Professor Pharmacy Practice and Science Department College of Pharmacy University of Kentucky Lexington, Kentucky A New Paradigm
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationFirst Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy
April 22, 2016 First Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma (PRINCETON,
More informationMay 20, Attached from the following page is the press release made by BMS for your information.
May 20, 2016 European Commission Approves the First and Only Immuno-Oncology Combination, Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen, for Treatment of Advanced Melanoma (PRINCETON, NJ, May 11, 2016)
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OPDIVO nivolumab Intravenous Infusion, 10 mg nivolumab /ml 40 mg and 100 mg single-use vials Antineoplastic Pr OPDIVO has been issued marketing
More informationBristol-Myers Squibb Receives FDA Approval for Opdivo
February 3, 2017 Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer (PRINCETON, N.J.,
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationAttached from the following page is the press release made by BMS for your information.
June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced
More informationKEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for
More informationJuly 19, Attached from the following page is the press release made by BMS for your information.
July 19, 2016 Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (PRINCETON, NJ, July 18,
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1 PRODUCT NAME KEYTRUDA 50 mg powder for solution for infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CAS No.: 1374853-91-4 One vial contains 50 mg of pembrolizumab. After reconstitution,
More informationComplications of Immunotherapy
Complications of Immunotherapy Sarah Norskog, PharmD, BCOP Oncology Pharmacy Specialist University of Colorado Hospital Disclosures I have no relevant financial relationships with commercial interests
More informationIpilimumab Monotherapy
INDICATIONS FOR USE: Ipilimumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of advanced (unresectable or metastatic) melanoma in adults C43 00105a ODMS *If a reimbursement indicator
More informationCANCER IMMUNOTHERAPY. Pocket Guide
CANCER IMMUNOTHERAPY Pocket Guide Unique Clinical Features Tumor Response Kinetics Response patterns associated with immune checkpoint blockade may differ from those associated with conventional therapies,
More informationUMN request : information to be made public Page 1
Product Name Active substance Opdivo Nivolumab (BMS 936558) UMN request : information to be made public Page 1 Indication and conditions of use Nivolumab (Opdivo)) is registered by the EMA for the treatment
More informationMay 24, Attached from the following page is the press release made by BMS for your information.
May 24, 2016 Two-Year Overall Survival Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer (PRINCETON, NJ, May 18, 2016) Bristol-Myers
More informationImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Jeryl Villadolid
More informationBCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab
BCCA Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Nivolumab Protocol Code Tumour Group Contact Physician USMAVNIV Skin and Melanoma Dr. Kerry Savage ELIGIBILITY: Unresectable
More informationIpilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.
Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose
More informationOpdivo (nivolumab) and Yervoy
June 8, 2016 Opdivo (nivolumab) and Yervoy (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer In Updated Phase 1b CheckMate -012 (PRINCETON,
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OPDIVO nivolumab Intravenous Infusion, 10 mg nivolumab /ml 40 mg and 100 mg single-use vials Antineoplastic Pr OPDIVO has been issued marketing
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationKEYTRUDA Pembrolizumab
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION KEYTRUDA Pembrolizumab powder for solution for infusion 50 mg solution for infusion 100 mg/4ml vial Antineoplastic agent, monoclonal antibody
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationPhase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma
November 18, 2016 Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma (PRINCETON, N.J., November 12, 2016)
More informationBristol-Myers Squibb s Opdivo
May 9, 2016 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma
More informationBCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab
BCCA Protocol Summary for Treatment of Advanced Non-Small Cell Lung Cancer Using Nivolumab Protocol Code Tumour Group Contact Physician ULUAVNIV Lung Dr. Christopher Lee ELIGIBILITY: Advanced non-small
More information